TWD
RXRX icon

True Wealth Design’s Recursion Pharmaceuticals RXRX Stock Holding History

True Wealth Design’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$712 Buy
194
+186
+2,325% +$619 ﹤0.01% 2095
2026
Q1 		$25 Buy
+8
New +$31 ﹤0.01% 2628
2025
Q2 		– Sell
-485
Closed -$2.57K – 2799
2025
Q1 		$2.57K Buy
+485
New +$3.54K ﹤0.01% 923

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

True Wealth Design's RXRX Position: Q2 2026 in Review

True Wealth Design increased its Recursion Pharmaceuticals (RXRX) stake by 2,325% in Q2 2026, buying an estimated $619 and bringing the position to 194 shares worth $712. The position accounts for ﹤0.01% of the portfolio, ranked #2095.

True Wealth Design first reported a position in RXRX in Q1 2025 and has held it in 3 quarters since. The position peaked at $2.57K in Q1 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • True Wealth Design held 194 shares of Recursion Pharmaceuticals worth $712 as of Q2 2026.
  • True Wealth Design bought 186 Recursion Pharmaceuticals shares in Q2 2026, an estimated $619.
  • Recursion Pharmaceuticals made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2095 holding.
  • True Wealth Design first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • True Wealth Design's Recursion Pharmaceuticals position peaked at $2.57K in Q1 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.